國立高雄大學圖資館 |

語系: 繁體中文

說明(常見問題)

圖資館首頁

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Preclinical evaluation of antimicrob...

Bueno, Juan.

Preclinical evaluation of antimicrobial nanodrugs

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Preclinical evaluation of antimicrobial nanodrugsby Juan Bueno.
作者:	Bueno, Juan.
出版者:	Cham :Springer International Publishing :2020.
面頁冊數:	xi, 117 p. :ill., digital ;24 cm.
Contained By:	Springer eBooks
標題:	Anti-infective agents.
電子資源:	https://doi.org/10.1007/978-3-030-43855-5
ISBN:	9783030438555$q(electronic bk.)

Preclinical evaluation of antimicrobial nanodrugs
Bueno, Juan.

Preclinical evaluation of antimicrobial nanodrugs[electronic resource] /by Juan Bueno. - Cham :Springer International Publishing :2020. - xi, 117 p. :ill., digital ;24 cm. - Nanotechnology in the life sciences,2523-8027. - Nanotechnology in the life sciences..

Preface -- 1. Antimicrobial screening, foundations and interpretation -- 2. Antimicrobial activity of nanomaterials, from selection to application -- 3. Synergy and antagonism, the criteria of the formulation -- 4. In vitro Nanotoxicity, towards the development of safe and effective treatments -- 5. ADMETox, bringing nanotechnology closer to Lipinski's rule of five -- 6. Antimicrobial nanotechnology in preventing the transmission of infectious disease -- 7. Nanotechnology in the discovery of new antimicrobial drugs: is a new scientific revolution possible? -- 8. Nanotechnology beyond the antibiosis -- Index.

Translational medicine addresses the gap between research and the clinical application of new discoveries. To efficiently deliver new drugs to care centers, a preclinical evaluation, both in vitro and in vivo, is required to ensure that the most active and least toxic compounds are selected as well as to predict clinical outcome. Antimicrobial nanomedicines have been shown to have higher specificity in their therapeutic targets and the ability to serve as adjuvants, increasing the effectiveness of pre-existing immune compounds. The design and development of new standardized protocols for evaluating antimicrobial nanomedicines is needed for both the industry and clinical laboratory. These protocols must aim to evaluate laboratory activity and present models of pharmacokinetic-pharmacodynamic and toxicokinetic behavior that predict absorption and distribution. Likewise, these protocols must follow a theranostics approach, be able to detect promising formulations, diagnose the infectious disease, and determine the correct treatment to implement a personalized therapeutic behavior. Given the possibilities that nanotechnology offers, not updating to new screening platforms is inadequate as it prevents the correct application of discoveries, increasing the effect of the valley of death between innovations and their use. This book is structured to discuss the fundamentals taken into account for the design of robust, reproducible and automatable evaluation platforms. These vital platforms should enable the discovery of new medicines with which to face antimicrobial resistance (RAM), one of the great problems of our time.

ISBN: 9783030438555$q(electronic bk.)

Standard No.: 10.1007/978-3-030-43855-5doiSubjects--Topical Terms:

204538
Anti-infective agents.

LC Class. No.: RM267 / .B846 2020

Dewey Class. No.: 615.792

Preclinical evaluation of antimicrobial nanodrugs
LDR:03224nmm a2200337 a 4500 001 579361
003 DE-He213
005 20200918132522.0
006 m
007 cr
008 201229s2020
020 $a 9783030438555$q(electronic bk.)
020 $a 9783030438548$q(paper)
024 7 $a 10.1007/978-3-030-43855-5 $2 doi
035 $a 978-3-030-43855-5
040 $a GP $c GP
041 0 $a eng
050 4 $a RM267 $b .B846 2020
072 7 $a MMFM $2 bicssc
072 7 $a MED052000 $2 bisacsh
072 7 $a MKFM $2 thema
082 0 4 $a 615.792 $2 23
090 $a RM267 $b .B928 2020
100 1 $a Bueno, Juan. $3 868730
245 1 0 $a Preclinical evaluation of antimicrobial nanodrugs $h [electronic resource] / $c by Juan Bueno.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2020.
300 $a xi, 117 p. : $b ill., digital ; $c 24 cm.
490 1 $a Nanotechnology in the life sciences, $x 2523-8027
505 0 $a Preface -- 1. Antimicrobial screening, foundations and interpretation -- 2. Antimicrobial activity of nanomaterials, from selection to application -- 3. Synergy and antagonism, the criteria of the formulation -- 4. In vitro Nanotoxicity, towards the development of safe and effective treatments -- 5. ADMETox, bringing nanotechnology closer to Lipinski's rule of five -- 6. Antimicrobial nanotechnology in preventing the transmission of infectious disease -- 7. Nanotechnology in the discovery of new antimicrobial drugs: is a new scientific revolution possible? -- 8. Nanotechnology beyond the antibiosis -- Index.
520 $a Translational medicine addresses the gap between research and the clinical application of new discoveries. To efficiently deliver new drugs to care centers, a preclinical evaluation, both in vitro and in vivo, is required to ensure that the most active and least toxic compounds are selected as well as to predict clinical outcome. Antimicrobial nanomedicines have been shown to have higher specificity in their therapeutic targets and the ability to serve as adjuvants, increasing the effectiveness of pre-existing immune compounds. The design and development of new standardized protocols for evaluating antimicrobial nanomedicines is needed for both the industry and clinical laboratory. These protocols must aim to evaluate laboratory activity and present models of pharmacokinetic-pharmacodynamic and toxicokinetic behavior that predict absorption and distribution. Likewise, these protocols must follow a theranostics approach, be able to detect promising formulations, diagnose the infectious disease, and determine the correct treatment to implement a personalized therapeutic behavior. Given the possibilities that nanotechnology offers, not updating to new screening platforms is inadequate as it prevents the correct application of discoveries, increasing the effect of the valley of death between innovations and their use. This book is structured to discuss the fundamentals taken into account for the design of robust, reproducible and automatable evaluation platforms. These vital platforms should enable the discovery of new medicines with which to face antimicrobial resistance (RAM), one of the great problems of our time.
650 0 $a Anti-infective agents. $3 204538
650 0 $a Nanomedicine. $3 273406
650 1 4 $a Medical Microbiology. $3 273931
650 2 4 $a Microbial Genetics and Genomics. $3 273651
650 2 4 $a Nanotechnology. $3 193873
650 2 4 $a Pharmaceutical Sciences/Technology. $3 338426
650 2 4 $a Plant Breeding/Biotechnology. $3 275234
650 2 4 $a Plant Biochemistry. $3 275238
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer eBooks
830 0 $a Nanotechnology in the life sciences. $3 821819
856 4 0 $u https://doi.org/10.1007/978-3-030-43855-5
950 $a Biomedical and Life Sciences (Springer-11642)